Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
33858718
DOI
10.1016/j.vaccine.2021.03.085
PII: S0264-410X(21)00401-1
Knihovny.cz E-zdroje
- Klíčová slova
- Children, Efficacy, Live-attenuated varicella vaccine, Long-term follow-up, Measles-mumps-rubella, Varicella zoster virus,
- MeSH
- dítě MeSH
- kojenec MeSH
- kombinované vakcíny škodlivé účinky MeSH
- lidé MeSH
- následné studie MeSH
- příušnice * MeSH
- protilátky virové MeSH
- spalničky * MeSH
- vakcína proti planým neštovicím škodlivé účinky MeSH
- vakcína proti spalničkám, příušnicím a zarděnkám MeSH
- zarděnky * prevence a kontrola MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
- Evropa MeSH
- Polsko MeSH
- Rumunsko MeSH
- Slovenská republika MeSH
- Názvy látek
- kombinované vakcíny MeSH
- protilátky virové MeSH
- vakcína proti planým neštovicím MeSH
- vakcína proti spalničkám, příušnicím a zarděnkám MeSH
BACKGROUND: We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. METHODS: This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12-22 months from 10 European countries were randomized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirmed by viral DNA detection or epidemiological link and clinical assessment) was calculated with 95% confidence intervals using Cox proportional hazards regression model. Immunogenicity was assessed as seropositivity rates and geometric mean concentrations (GMCs). Solicited and unsolicited adverse events (AEs) and serious AEs (SAEs) were recorded. RESULTS: A total of 3705 children were vaccinated (1590, MMRV group; 1586, MMR + V group; 529, MMR group). There were 663 confirmed varicella cases (47, MMRV group; 349, MMR + V group; 267, MMR group). VE ranged between 95.4% (Lithuania) and 97.4% (Slovakia) in the MMRV group and between 59.3% (Lithuania) and 74% (Slovakia) in the MMR + V group. At year 10, seropositivity rates were 99.5%-100% in the MMRV group, 98%-100% in the MMR + V group and 50%-100% in the MMR control group, and the anti-VZV antibody GMCs were comparable between MMRV and MMR + V groups. The occurrence of solicited and unsolicited AEs was similar across groups and no SAE was considered as vaccination-related. No new safety concerns were identified. CONCLUSIONS: Our results indicated that two doses of varicella zoster virus-containing vaccine provided better protection than one dose against varicella and induced antibody responses that persisted 10 years post-vaccination.
Charles University Faculty of Medicine Hradec Kralove Czech Republic
Department of Epidemiology Medical Faculty Pilsen of Charles University Czech Republic
Faculty of Health Care Alexander Dubcek University of Trencín Trencín Slovakia
Lucian Blaga University of Sibiu Faculty of Medicine Sibiu Romania
Nemocnice s ambulantni casti Jindrichuv Hradec Czech Republic
Paediatric Centre Prague Czech Republic
Pediatric Clinic Lithuanian University of Health Sciences Kaunas Lithuania
Pediatric Office Dr Renata Ruzkova Prague Czech Republic
Pediatrics University of Medicine and Pharmacy Carol Davila Bucharest Romania
Poradnia Chorob Zakaznych ZOZ Debica Debica Poland
University of Defence Faculty of Military Health Sciences Hradec Kralove Czech Republic
University of Medical Sciences Poznan Poland
University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca Romania
Citace poskytuje Crossref.org